Celprogen’s Novel Cancer Stem Cell Drug Candidates Reduce Growth of
Pancreatic, Colon, Melanoma and Glioblastoma Tumors
CEOCFO: Mr. Sharma, what is the main thrust for Celprogen today?
Mr. Sharma: Celprogen remains focused on developing novel non-toxic drugs against
cancers of the pancreas, colon, lung, skin and brain.
CEOCFO: Why those particular areas?
Mr. Sharma: Cancers in these target organs are challenging based on current treatment
paradigms and can benefit from Celprogen’s novel drugs aimed to improve the life
expectancy of patients who currently succumb to their disease.
To read full article, click here.